Business
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a community forum for open discussion about HS, a dermatologic disease that remains both underdiagnosed and often misdiagnosed.2-3 By bringing stakeholders together, UCB sought to foster a deeper understanding of HS and address the challenges associated with it.
About this update from Ucb S.a.
[{"type":"list","items":[{"val":[{"type":"text","content":"Building on the success of its inaugural event, the 2025 UCB HS Summit focused on amplifying the patient voice and tackling critical unmet needs in the HS community.","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"The event brought together over 100 people from across the HS community on the UCB Atlanta campus and featured interactive discussions and educational workshops focused on storytelling, wellness, nutrition, and advocating for care.","length":231,"tagName":"p"}]},{"val":[{"type":"text","content":"Summit sessions also focused on expanding and optimizing earlier treatment of individuals living with moderate-to-severe HS.","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"BIMZELX® (bimekizumab-bkzx) can deliver transformative relief of moderate-to-severe hidradenitis suppurativa (HS) symptoms, and patients can start to get themselves back.1 In two clinical studies of adult patients with moderate-to-severe HS, around 5 in 10 people saw a 50% reduction in the number of inflamed nodules and abscesses, with no increase in abscesses or tunnels at 16 weeks, vs. around 3 in 10 taking placebo.1","length":422,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":942,"olType":false},{"type":"text","content":"ATLANTA, Aug. 5, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a community forum for open discussion about HS, a dermatologic disease that remains both underdiagnosed and often misdiagnosed.2-3 By bringing stakeholders together, UCB sought to foster a deeper understanding of HS and address the challenges associated with it.","length":417,"tagName":"p"},{"type":"image","alt":"UCB U.S. Immunology leaders, including Rhonda Peebles (VP & Head of U.S. Dermatology), Dr. Jeffrey Stark (VP & Head of Medical Immunology, U.S.), and Camille Lee (Head of U.S. Immunology), are joined by Dr. Vivian Shi, professor at the University of Washington (UW) Department of Dermatology and a board-certified dermatologist at the UW Medical Center–Roosevelt Dermatology Center, in an opening panel discussion at the UCB HS Summit dedicated to advancing the care of hidradenitis suppurativa (HS).","displaySize":"","headline":null,"caption":"UCB U.S. Immunology leaders, including Rho...